Portola Pharmaceuticals Inc (PTLA)

25.92
0.01 0.04
NASDAQ : Health Care
Prev Close 25.93
Open 26.41
Day Low/High 25.75 / 26.47
52 Wk Low/High 18.20 / 57.95
Volume 634.50K
Avg Volume 637.40K
Exchange NASDAQ
Shares Outstanding 56.47M
Market Cap 1.42B
EPS -4.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Portola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock

Portola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a "perilous reversal" (up big yesterday but down big today) candidate

Monsanto, Amazon and Apple: Doug Kass' Views

Monsanto, Amazon and Apple: Doug Kass' Views

Doug Kass shares his thoughts on shorting financials, and wonders if it will be a Monsanto merger Monday.

Portola Pharmaceuticals Becomes Oversold (PTLA)

Portola Pharmaceuticals Becomes Oversold (PTLA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

Perilous Reversal Stock: Portola Pharmaceuticals (PTLA)

Perilous Reversal Stock: Portola Pharmaceuticals (PTLA)

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a "perilous reversal" (up big yesterday but down big today) candidate

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo To Develop Andexanet Alfa With Edoxaban In Japan

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo To Develop Andexanet Alfa With Edoxaban In Japan

Development and Commercialization of Andexanet Alfa In Japan Fully Supported by Collaboration Partners

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says

Portola Pharmaceuticals (PTLA) Is Today's Dead Cat Bounce Stock

Portola Pharmaceuticals (PTLA) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Here’s Why Portola Pharmaceuticals (PTLA) Stock is Falling Today

Here’s Why Portola Pharmaceuticals (PTLA) Stock is Falling Today

Portola Pharmaceuticals (PTLA) stock is dropping late Monday afternoon as Goldman Sachs downgraded the stock and the company reported disappointing trial results last week.

Portola Pharmaceuticals (PTLA) Weak On High Volume Today

Portola Pharmaceuticals (PTLA) Weak On High Volume Today

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a weak on high relative volume candidate

Why Portola Pharmaceuticals (PTLA) Stock is Plunging Today

Why Portola Pharmaceuticals (PTLA) Stock is Plunging Today

Portola Pharmaceuticals (PTLA) stock is tumbling on heavy trading volume on Thursday afternoon the company said its oral treatment for blood clots is not statistically different than the current standard.

Portola Pharmaceuticals (PTLA) Stock Falls on Blood Clot Trial Results

Portola Pharmaceuticals (PTLA) Stock Falls on Blood Clot Trial Results

Portola Pharmaceuticals (PTLA) stock is down after the company said its oral treatment for blood clots was not statistically different than the current standard of care.

Heavy Trading On Portola Pharmaceuticals (PTLA) Before Market Open

Heavy Trading On Portola Pharmaceuticals (PTLA) Before Market Open

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a pre-market mover with heavy volume candidate

Tesla, Amazon and Netflix: Doug Kass' Views

Tesla, Amazon and Netflix: Doug Kass' Views

Doug Kass shares his views on why technicals bode ill for tech.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.